{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:27:12Z","timestamp":1784068032914,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clbc.2024.01.009","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T15:09:48Z","timestamp":1705849788000},"page":"301-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["New Strategies for Locally Advanced Breast Cancer: A Review of Inflammatory Breast Cancer and Nonresponders"],"prefix":"10.1016","volume":"24","author":[{"given":"Simran","family":"Malhotra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audree B.","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2024.01.009_bib0001","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.suc.2018.03.009","article-title":"Inflammatory breast cancer: what to know about this unique, aggressive breast cancer","volume":"98","author":"Menta","year":"2018","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.clbc.2024.01.009_bib0002","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/annonc\/mdt525","article-title":"Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes","volume":"25","author":"Masuda","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0003","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2012-0039","article-title":"Inflammatory breast cancer: what we know and what we need to learn","volume":"17","author":"Yamauchi","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2024.01.009_bib0004","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1245\/s10434-017-5952-x","article-title":"Improved locoregional control in a contemporary cohort of nonmetastatic inflammatory breast cancer patients undergoing surgery","volume":"24","author":"Rosso","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3322\/caac.20082","article-title":"Inflammatory breast cancer: the disease, the biology, the treatment","volume":"60","author":"Robertson","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clbc.2024.01.009_bib0006","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10549-021-06434-x","article-title":"Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research","volume":"192","author":"Jagsi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.01.009_bib0007","article-title":"Development of a multi-institutional, photograph-rich clinical dataset to test and validate a novel inflammatory breast cancer (IBC) scoring system","author":"Lynce","year":"2023","journal-title":"San Antonio Breast Cancer Symposium"},{"key":"10.1016\/j.clbc.2024.01.009_bib0008","doi-asserted-by":"crossref","first-page":"58","DOI":"10.21037\/cco-21-116","article-title":"Why diagnosing inflammatory breast cancer is hard and how to overcome the challenges: a narrative review","volume":"10","author":"Le-Petross","year":"2021","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0009","doi-asserted-by":"crossref","first-page":"W769","DOI":"10.2214\/AJR.10.6157","article-title":"MRI features of inflammatory breast cancer","volume":"197","author":"Le-Petross","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1148\/rg.2021200134","article-title":"Breast MRI for evaluation of response to neoadjuvant therapy","volume":"41","author":"Reig","year":"2021","journal-title":"Radiographics"},{"key":"10.1016\/j.clbc.2024.01.009_bib0011","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jamcollsurg.2021.04.016","article-title":"Reconstruction in women with T4 breast cancer after neoadjuvant chemotherapy: when is it safe?","volume":"233","author":"Pawloski","year":"2021","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.clbc.2024.01.009_bib0012","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2024.01.009_bib0013","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s002800050664","article-title":"Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center","volume":"40","author":"Ueno","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0014","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2012.45.0940","article-title":"Response-guided neoadjuvant chemotherapy for breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0015","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1245\/s10434-020-08593-5","article-title":"How often does modern neoadjuvant chemotherapy downstage patients to breast-conserving surgery?","volume":"28","author":"Petruolo","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0016","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2024.01.009_bib0017","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","article-title":"Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes","volume":"30","author":"von Minckwitz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0018","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.breast.2021.11.009","article-title":"Pathology after neoadjuvant treatment: how to assess residual disease","volume":"62","author":"Viale","year":"2022","journal-title":"The Breast"},{"key":"10.1016\/j.clbc.2024.01.009_bib0019","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0020","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1200\/JCO.2015.63.1010","article-title":"Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype","volume":"35","author":"Symmans","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0021","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.annonc.2019.10.012","article-title":"Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges","volume":"31","author":"Heil","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0022","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-021-06184-w","article-title":"Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial","volume":"188","author":"Masuda","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.01.009_bib0023","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_sbref0025","series-title":"In: StatPearls [Internet]","article-title":"Postmastectomy breast cancer radiation therapy","author":"Remick","year":"2024"},{"key":"10.1016\/j.clbc.2024.01.009_bib0026","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1245\/s10434-022-12457-5","article-title":"ASO visual abstract: long-term oncologic outcomes in patients with inflammatory breast cancer with supraclavicular nodal involvement","volume":"29","author":"Cobb","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0027","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.prro.2019.05.011","article-title":"Excellent locoregional control in inflammatory breast cancer with a personalized radiation therapy approach","volume":"9","author":"Stecklein","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0028","doi-asserted-by":"crossref","first-page":"57","DOI":"10.21037\/cco-21-113","article-title":"Contemporary surgical management of inflammatory breast cancer: a narrative review","volume":"10","author":"Adesoye","year":"2021","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0029","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1245\/s10434-022-12560-7","article-title":"Patient-reported outcome measures for patients who have clinical T4 breast cancer treated via mastectomy with and without reconstruction","volume":"30","author":"Palmquist","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0030","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0031","unstructured":"The ASCO Post Staff. Combining ribociclib with hormone therapy improves patient outcomes in early-stage breast cancer: NATALEE. The ASCO Post. December 8, 2023. Available at: https:\/\/ascopost.com\/news\/december-2023\/combining-ribociclib-with-hormone-therapy-improves-patient-outcomes-in-early-stage-breast-cancer-natalee\/. Accessed February 19, 2024."},{"key":"10.1016\/j.clbc.2024.01.009_bib0032","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0033","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0034","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0035","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0036","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0037","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2016.70.8297","article-title":"Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer","volume":"35","author":"Bardia","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0038","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0039","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s12282-022-01389-3","article-title":"Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance","volume":"29","author":"Zhu","year":"2022","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2024.01.009_bib0040","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0041","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0042","unstructured":"AstraZeneca. A phase 3 open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared to ddAC-THP in participants with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11). Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05113251. Accessed October 27, 2023."},{"key":"10.1016\/j.clbc.2024.01.009_bib0043","unstructured":"Lynce FT. A phase II study of neoadjuvant trastuzumab deruxtecan and durval-umab for stage III, HER2-expressing inflammatory breast cancer. Available at: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05795101. Accessed February 19, 2024."},{"key":"10.1016\/j.clbc.2024.01.009_bib0044","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13014-019-1320-2","article-title":"Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer","volume":"14","author":"Choi","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231164537","article-title":"Palliative radiotherapy for symptomatic locally advanced breast cancer","volume":"22","author":"Hoeltgen","year":"2023","journal-title":"Technol Cancer Res Treat"},{"issue":"6","key":"10.1016\/j.clbc.2024.01.009_bib0046","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/j.prro.2023.05.011","article-title":"Preoperative radiation therapy for chemorefractory localized inflammatory breast cancer","volume":"13","author":"Rog\u00e9","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0047","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.radonc.2012.01.008","article-title":"Effect of preoperative rescue concomitant FUN\/XUN-based chemo-radiotherapy for neoadjuvant chemotherapy-refractory breast cancer","volume":"103","author":"Bourgier","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0048","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1245\/s10434-021-10764-x","article-title":"Local recurrence is frequent after heroic mastectomy for classically inoperable breast cancers","volume":"29","author":"Mamtani","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0049","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(22)00145-0","article-title":"Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study","volume":"23","author":"Thiruchelvam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0050","unstructured":"Memorial Sloan Kettering Cancer Center. Feasibility of preoperative radiotherapy in T3 and T4 breast cancer patients who are responders to neoadjuvant chemotherapy to allow for immediate reconstruction: a prospective study. https:\/\/clinicaltrials.gov\/study\/NCT05412225. Accessed October 27, 2023."},{"key":"10.1016\/j.clbc.2024.01.009_bib0051","unstructured":"Center MDAC. Trial Of preoperative radiation (TOPAz): a randomized trial comparing hypofractionated versus conventionally fractionated preoperative radiation followed by mastectomy with immediate autologous breast reconstruction with integrated nanomechanical biomarker evaluation: clinicaltrials.gov; 2023."},{"key":"10.1016\/j.clbc.2024.01.009_bib0052","unstructured":"A randomized study of preoperative chemotherapy, pembrolizumab and no, low or high dose radiation in node-positive, HER2-negative breast cancer: clinicaltrials.gov; 2023."},{"key":"10.1016\/j.clbc.2024.01.009_bib0053","unstructured":"National cancer I. A phase II randomized trial of olaparib (NSC-747856) administered concurrently with radiotherapy versus radiotherapy alone for inflammatory breast cancer: clinicaltrials.gov; 2023."},{"key":"10.1016\/j.clbc.2024.01.009_bib0054","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.1245\/s10434-022-12142-7","article-title":"Lymphedema in inflammatory breast cancer patients following trimodal treatment","volume":"29","author":"Farley","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-med-060116-022900","article-title":"Lymphedema: pathogenesis and novel therapies","volume":"69","author":"Dayan","year":"2018","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clbc.2024.01.009_bib0056","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/micr.22254","article-title":"Lymphatic microsurgical preventing healing approach (LYMPHA) for primary surgical prevention of breast cancer-related lymphedema: over 4 years follow-up","volume":"34","author":"Boccardo","year":"2014","journal-title":"Microsurgery"},{"key":"10.1016\/j.clbc.2024.01.009_bib0057","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/SLA.0000000000005952","article-title":"Efficacy of immediate lymphatic reconstruction to decrease incidence of breast cancer-related lymphedema: preliminary results of randomized controlled trial","volume":"278","author":"Coriddi","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2024.01.009_bib0058","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/SLA.0000000000000763","article-title":"Vascularized lymph node transfer for treatment of lymphedema: a comprehensive literature review","volume":"261","author":"Raju","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.clbc.2024.01.009_bib0059","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/s-0038-1632401","article-title":"Vascularized lymph node transfer for lymphedema","volume":"32","author":"Schaverien","year":"2018","journal-title":"Semin Plast Surg"},{"key":"10.1016\/j.clbc.2024.01.009_bib0060","first-page":"e6227","article-title":"Omental lymph node transfer for lymphedema patients: a systematic review","volume":"11","author":"Forte","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.clbc.2024.01.009_bib0061","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/jso.25033","article-title":"Double vascularized omentum lymphatic transplant (VOLT) for the treatment of lymphedema","volume":"117","author":"Kenworthy","year":"2018","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0062","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.clbc.2017.06.014","article-title":"Prospective feasibility trial of sentinel lymph node biopsy in the setting of inflammatory breast cancer","volume":"18","author":"DeSnyder","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2024.01.009_bib0063","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02573060","article-title":"Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer","volume":"9","author":"Stearns","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0064","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijsu.2009.04.012","article-title":"Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer","volume":"7","author":"Hidar","year":"2009","journal-title":"Int J Surg"},{"key":"10.1016\/j.clbc.2024.01.009_bib0065","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000512202","article-title":"Sentinel lymph node biopsy may prevent unnecessary axillary dissection in patients with inflammatory breast cancer who respond to systemic treatment","volume":"16","author":"Karanlik","year":"2020","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2024.01.009_bib0066","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejso.2020.10.014","article-title":"Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up","volume":"47","author":"Kahler-Ribeiro-Fontana","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0067","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1245\/s10434-020-08900-0","article-title":"Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer","volume":"27","author":"Piltin","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0068","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1245\/s10434-020-09211-0","article-title":"Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer","volume":"28","author":"Wong","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0069","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1245\/s10434-022-12138-3","article-title":"Inflammatory breast cancer: is there a role for deescalation of surgery?","volume":"29","author":"Nakhlis","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clbc.2024.01.009_bib0070","unstructured":"Memorial Sloan Kettering Cancer Center. Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer: a prospective study. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03255577. Accessed October 27, 2023."},{"key":"10.1016\/j.clbc.2024.01.009_bib0071","doi-asserted-by":"crossref","unstructured":"Mamounas E, Bandos H, White J, et al. Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-Negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology\/NSABP B-51\/RTOG 1304 (Abstract GS02-07). Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, TX.","DOI":"10.1158\/1538-7445.SABCS23-GS02-07"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924000090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924000090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T16:36:11Z","timestamp":1742229371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924000090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":70,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1526820924000090"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.01.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Strategies for Locally Advanced Breast Cancer: A Review of Inflammatory Breast Cancer and Nonresponders","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}